Proprietary Platforms
MVA Platform
A Trusted Technology for Genetic Vaccines
Our Modified Vaccinia Ankara (MVA) platform is a well-established viral vector system optimized for vaccine development and clinical-grade manufacturing.
Why MVA?
1
Proven Safety & Versatility
Suitable for infectious disease vaccines, cancer immunotherapies, and personalized approaches.
2
Rapid Vector Development
Recombinant constructs are designed, cloned, and characterized in a pre-GMP setting—enabling fast turnaround.
3
Dual Manufacturing Options
Suspension (STR) and adherent (fixed bed) bioreactors support flexible, scalable production.
GMP Manufacturing Ready
- Full production in Grade B cleanrooms
- Validated processes for viral propagation, purification, and formulation
- Integrated QC and fill & finish operations for efficient release
Clinical-Grade, Field-Tested
High-performance equipment for production in suspension or cell growth in adherence
The MVA platform has delivered multiple GMP batches for clinical trials, spanning infectious disease, oncology, and personalized medicine. Its established performance ensures regulatory confidence and manufacturing reliability.
